Previous 10 | Next 10 |
2024-06-07 14:23:26 ET More on NASDAQ Composite Index, S&P 500 Index, etc. The Fed Preview: Hawkish Turn Straight Into The Recession S&P 500 Earnings: Forward Estimates Continue To Be Revised Higher May Jobs Report: Surging Payrolls Likely Temper Rate Expecta...
2024-06-07 12:46:11 ET More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus gains after early-stage data for cystic fibros...
ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF) Phase 1b interim data includes a CF participant with Class 1 mutations and three participants with F508del mutations being treated with Trik...
2024-05-30 11:50:35 ET Summary Vertex Pharmaceuticals has a strong focus on cystic fibrosis, which is driving revenue growth and pipeline development. The company has outperformed Johnson & Johnson and the S&P 500 in terms of total returns. Near-term catalysts include ...
2024-05-28 09:04:37 ET More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earn...
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two administrations Arcturus Therapeutics Holdings Inc. (the “Company”, ...
2024-05-22 14:00:26 ET More on BioNTech, Moderna, etc. Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs Aggressive Strides Forward For Moderna's Cancer Vaccine Pfizer Stock: Rebound Has Started (Technical Analysis) Pfizer launchi...
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These res...
2024-05-08 21:04:07 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Results Conference Call May 08, 2024 04:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President &...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...